Michael Engsig, CEO of
Since its founding in 2007, Nykode (formerly called Vaccibody), a biopharmaceutical company based in Norway, has been focused on realizing the full potential of cancer immunotherapy by developing cutting-edge, targeted DNA-based vaccines for clinical use. One of their lead programs is focused on targeting neoantigens – foreign proteins expressed specifically on the surface of tumor cells – which may be an effective approach for harnessing a person’s immune system to fight cancer.
But bringing new treatment approaches like individualized cancer vaccines to patients takes time and requires collaboration with equally passionate partners. In 2020, Nykode and Genentech established a partnership to develop individualized neoantigen cancer vaccines against different types of solid tumors. From the start, this collaboration has been a success.
“Genentech is a scientific pioneer within the neoantigen cancer vaccine space. I’ve been really impressed with the collaborative spirit,” Engsig says. “Fortunately, there’s been a fantastic cultural fit between our teams.”
Don O’Sullivan, head of Roche Pharma Partnering for Oncology, agrees that together, the scientists can accelerate our understanding of the science behind cancer immunotherapy. “This collaboration with Nykode maximizes our chances of treating cancer patients with neoantigen vaccines,” he says. “It has the potential to transform the treatment landscape for many types of cancers.”
If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.